Dr. Sheng Pan, Ph.D.

Dr. Sheng Pan, Ph.D.

Associate Professor, Center for Precision Biomedicine

Email Address: Sheng.Pan@uth.tmc.edu
Phone Number: 713-486-5428
Room Number: SRB 330H

Narrative

Dr. Pan’s lab is interested in applying mass spectrometry based proteomics and other molecular techniques to study disease-associated proteome alterations at a functional level. These studies are carried out with various goals, aiming to better understand the molecular mechanisms underlying tumorigenesis, to investigate changes in PTM status associated with diseases, and to identify cancer associated protein biomarkers to improve diagnosis or therapeutic treatment. Currently, our main disease focuses are pancreatic ductal adenocarcinoma, as well as other GI-tract malignancies and chronic inflammatory diseases. In addition, through collaborative efforts, our lab also supports proteomics investigation of neurological diseases, other types of cancers, GI-tract microbiome, infectious diseases and therapeutic drug development. Bioinformatics and systems biology are important components in our study for analysis of protein interaction networks and regulatory pathways associated with cancer and other disease mechanisms. Our works aim to apply and innovate clinical proteomics to facilitate mechanistic studies and biomarker discovery to facilitate early detection, treatment selection and drug development.

Current research interests include:

  • Discovery of protein biomarkers and drug targets in pancreatic cancer and other GI-tract diseases
  • Investigation of alterations and macroheterogeneity of protein N-glycosylation in malignancies and other diseases
  • Mass spectrometric characterization of protein PTMs and adducts in association with cancer and other diseases
  • Innovation of proteomics technologies for clinical applications

Selected Publications:

    1. Chen R, Lai LA, Sullivan Y, Wong M, Wang L, Riddell J, Jung L, Pillarisetty VG, Brentnall1 TA, Pan S, “Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer”, Scientific Reports, 2017, ;7(1):7950.
    2. N Nigjeh E, Chen R, Brand RE, Petersen GM, Chari ST, von Haller PD, Eng JK, Feng Z, Yan Q, Brentnall TA, Pan S, “Quantitative Proteomics Based on Optimized Data-independent-acquisition in Plasma Analysis”, Journal of Proteome Research. 2017, 16(2):665-676.
    3. Chen R, Dawson DW, Pan S, Ottenhof NA, de Wilde RF, Wolfgang CL, May DH, Crispin DA, Lai LA, Lay AR, Waghray M, Wang S, McIntosh MW, Simeone DM, Maitra A, and Brentnall TA, “Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma”, Laboratory Investigation,  2015, 95(1):43-55.
    4. Pan S, Chen R, Tamura1 Y, Crispin DA, Lai LA, May DH, McIntosh MW, Goodlett DR and Brentnall TA, “Quantitative glycoproteomics analysis reveals changes in N-glycosylation level associated with pancreatic ductal adenocarcinoma”, Journal of Proteome Research. 2014 13(3):1293-1306.
    5. Pan S, Chen R, Brand RE, Hawley S, Tamura Y, Gafken PR, Milless BP, David R. Goodlett DR, Rush J and Brentnall1 TA, “A multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study”, Journal of Proteome Research. 2012, 11, 1937-1948.
    6. Pan S, Chen R, Stevens T, Bronner MP, May D, Tamura Y, McIntosh MW and Brentnall TA, “Proteomics portrait of archival lesions of chronic pancreatitis”, PLoS ONE 2011, 6(11):e27574.
    7. Pan S, Chen R, Crispin DA, May D, Stevens T, McIntosh MW, Bronner MP, Anton-Culver H, Ziogas A and Brentnall1 TA, “Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profiling”, Journal of Proteome Research.
    8. May D , Pan S, Crispin D, Lai K, Bronner MP, Hogan J, Hockenbery DM, McIntosh MW, Brentnall TA and Chen R, “Investigating neoplastic progression of ulcerative colitis with label-free comparative proteomics”, Journal of Proteome Research. 2011, 7, 200-209.
    9. Pan S, Chen R, Reimel BA, Crispin DA, Mirzaei H, Cooke K, Coleman JF, Lane Z, Bronner MP, Goodlett DR, McIntosh MW, Traverso W, Aebersold R and Brentnall TA, “Quantitative proteomics investigation of pancreatic intraepithelial neoplasia”, Electrophoresis. 2009, 30, 1132-1144.
    10. Pan S, Rush J, Peskind ER, Galasko D, Chung K, Quinn J, Jankovic J, Leverenz JB, Zabetian C, Pan C, Wang Y, Oh JH, Gao J, Zhang J, Montine T and Zhang J, “Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using an LC MALDI TOF/TOF platform”, Journal of Proteome Research. 2008, 7, 720-730.
    11. Pan S, Wang Y, Quin JF, Pesking ER, Waichunas D, Wimberger JT, Jin J, Li J, Zhu D, Pan C and Zhang J, “Identification of glycoproteins in human cerebrospinal fluid with a complementary proteomic approach”, Journal of Proteome Research. 2006, 5, 2769-2779.
    12. Pan S, Zhang H, Rush J, Eng J, Zhang N, Patterson D, Comb MJ and Aebersold R, “High-throughput proteome screening for biomarker detection”, Molecular & Cellular Proteomics. 2005, 4, 182-190.